← Eichor
Study identifier: NCT06498167 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Condition: Inflammatory Disease · Drug Side Effect · Drug Use  ·  Sponsor: Universidade do Porto

PhaseN/A
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \& Co. KG.

This description comes directly from the study's public registry record.

Talk to the study team

Inês Ribeiro Vaz, PharmD, MPH, PhD  ·  + 351220426952  ·  inesvaz@med.up.pt

Renato Ferreira da Silva, PharmD  ·  +351220426913  ·  rsilva@med.up.pt

Always discuss trial participation with your own doctor first.

Locations (3)

Unidade Local de Saúde de Santo António, E.P.E.Porto, PortugalActive Not Recruiting
Unidade Local de Saúde de São João, E.P.E.Porto, PortugalRecruiting
Unidade Local de Saúde de Gaia/Espinho, E.P.E.Porto, PortugalActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06498167